Who are RAPT Therapeutics's investors?

RAPT Therapeutics's investors include Frazier Life Sciences, Kleiner Perkins, Solasta Ventures, The Column Group, OrbiMed.

RAPT Therapeutics

Founded 2015 · 120 employees on LinkedIn · 5 known investors

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases. Its pipeline includes ozureprubart, a long-acting anti-IgE antibody being developed for food allergy.

Biotech Healthtech

Investors · 5

Frazier Life SciencesPalo Alto

Kleiner PerkinsMenlo Park · $500K – $15M

Solasta VenturesBoston

The Column GroupSan Francisco · $30M

OrbiMedreportedNew York · $1M – $75M

Funding

SEC filings, press & company announcements

Undisclosed amountprivate placementDec 2024
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through RAPT Therapeutics went on to found or lead other companies.

Wendye RobbinsMember Board of Directors, Audit, Transaction, and Pricing CommitteesFounded Limerick Biopharma +1 Dennis X. HuScientist II, Drug DiscoveryFounded Drughunter

In the news

RAPT Stock Price, News & Analysis | Rapt Therapeuticsstocktitan.net · Jun 2026

GSK to Acquire RAPT Therapeutics for $2.2 Billion, Targeting Food Allergy Treatments - Alpha Spreadalphaspread.com · Jan 2026

RAPT Therapeutics Partners with Jemincare and Secures Funding - TipRanks.comtipranks.com · Dec 2024

RAPT Therapeutics Secures Massive $150M Private Placement Led by Healthcare Investment Giants | RAPT Stock Newsstocktitan.net · Dec 2024

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September - RAPT Therapeuticsrapt.com · Sep 2023

Frequently asked questions

What does RAPT Therapeutics do?: RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases. Its pipeline includes ozureprubart, a long-acting anti-IgE antibody being developed for food allergy.
Who are RAPT Therapeutics's investors?: RAPT Therapeutics's investors include Frazier Life Sciences, Kleiner Perkins, Solasta Ventures, The Column Group, OrbiMed.